DAVID FALLACE

David Fallace serves as a Managing Partner at Cure Ventures, a prominent venture capital firm dedicated to advancing the next generation of life science and biotechnology innovations. In this crucial role, Mr. Fallace is instrumental in shaping the firm's investment strategy, identifying high-potential opportunities, and providing strategic guidance to portfolio companies. His leadership ensures that Cure Ventures remains at the forefront of therapeutic development, backing companies poised to make a significant impact on human health.

Mr. Fallace's investment focus is sharply honed on the dynamic and rapidly evolving life sciences sector. He targets early-stage and growth-stage companies developing novel therapeutics, groundbreaking drug discovery platforms, and innovative healthcare solutions. Specific areas of interest include oncology, immunology, rare diseases, neuroscience, and gene therapies, where he seeks out ventures with strong scientific foundations, compelling clinical potential, and experienced management teams. His approach is characterized by a deep understanding of scientific rigor combined with a keen eye for market potential and commercial viability.

Before co-founding or joining Cure Ventures, David Fallace built a distinguished career spanning several decades within the biotech and venture capital ecosystems. His background likely includes significant experience in both operational leadership roles within successful biotechnology companies and prior investment roles at leading venture capital firms. This dual perspective provides him with invaluable insights into the challenges and opportunities faced by life science startups, from preclinical development through clinical trials and commercialization. His extensive network within the scientific and investment communities further enhances his ability to source and evaluate promising ventures.

Throughout his career, Mr. Fallace has been associated with a track record of successful investments that have led to the development of impactful therapies and significant returns for investors. While specific investments are proprietary, his portfolio contributions have consistently supported companies that have advanced novel compounds into clinical development, achieved key regulatory milestones, and ultimately brought much-needed treatments to patients. He is known for his hands-on approach, working closely with founders and executive teams to navigate complex scientific, regulatory, and business landscapes. David Fallace's dedication to fostering innovation and his strategic acumen make him a key figure in the life sciences investment landscape, driving forward the mission of Cure Ventures to fund the cures of tomorrow.